Asia
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.
Illumina, the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
BeiGene continues its roll with anti-PD-1 monoclonal antibody tislelizumab, announcing topline data yesterday from its fourth positive Phase III trial, this time in esophageal squamous cell carcinoma.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
A brief rundown of the biopharmas that brought in the cash the past week.
Daiichi Sankyo’s and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has become the first HER2-directed medication approved to treat gastric cancer in the U.S. in 10 years.
Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception.
PRESS RELEASES